New Treatments for Type 2 Diabetes
|
|
- Sherilyn Hampton
- 7 years ago
- Views:
Transcription
1 New Treatments for Type 2 Diabetes Dr David Hopkins Clinical Director, Division of Ambulatory Care King s College Hospital NHS Foundation Trust
2 Treatments for type 2 diabetes - old & new insulin sulphonylureas biguanides a-glucosidase meglitinides thiazolinediones GLP-1 analogues DPP IV inhibitors SGLT-2 inhibitors gliclazide etc. metformin acarbose repaglinide pioglitazone exenatide/liraglutide e.g. sitagliptin e.g. dapagliflozin
3 Treatments for type 2 diabetes - old & new Drugs that stimulate insulin secretion sulphonylureas gliclazide etc. meglitinides repaglinide Drugs that influence insulin action biguanides metformin thiazolinediones rosiglitazone Drugs that mimic/ increase GLP-1 GLP-1 analogues exenatide/liraglutde/ DPP IV inhibitors..gliptin Drugs that promote glycosuria SGLT-2 inhibitors dapagliflozin/canagliflozin
4 Sulphonylureas sulphonamide derivatives - first oral anti-diabetic agents stimulate insulin secretion from the pancreas act via K ATP channels on b-cell
5 Sulphonylureas strong evidence supporting use - first line agent in main UKPDS study cause significant weight gain significant risk of hypoglycaemia
6 Evolution of sulphonylureas 1st generation: chlorpropamide/glibenclamide long action, renal excretion high risk of hypos 2nd generation: gliclazide / glipizide etc hepatic metabolism - safer in elderly market leaders in UK 3 rd generation: glimepiride Once daily dosing Little difference from 2 nd generation
7 Metformin introduced in 1950s in Europe, but only licensed in USA in 1995 reduces hepatic glucose output and increases glucose uptake in muscle use now supported by UKPDS very cheap weight neutral GI side effects limiting in some patients contra-indicated in renal impairment
8 % risk reduction UKPDS 34. Lancet 1998;352: UKPDS - effects of metformin P= P=0.02 P=0.010 P=0.017 P= diabetes infarction related mortality related death
9 The Thiazolinediones selective agonists of PPAR g Troglitazone Glaxo 1997 (RIP) Rosiglitazone GSK (RIP) Pioglitazone Takeda 2000
10 PPAR -nuclear hormone receptors Receptors Thyroid Steroid Orphans PPARs Retinoic acid Thyroid hormones Steroid hormones PPARa PPAR PPARg RAR RXR
11 Troglitazone licensed in UK in 1997 as monotherapy or add-on treatment for type 2 diabetes rapidly withdrawn due to reports of liver toxicity Rosiglitazone Global blockbuster in top 10 of all drug sales Cardiovascular safety concerns raised in 2007 Subsequently withdrawn from the market
12 Pioglitazone Remains available and is an effective drug improves insulin action Some safety concerns fluid retention risk of exacerbation CCF increased fragility fractures possible association with bladder cancer
13 Venous Plasma Glucose (mmol/l) C-peptide (nmol/l) The Incretin effect Oral Glucose IV Glucose * * * * * Incretin Effect * 0.5 * Time (min) Time (min) Mean ± SE; N = 6; *P.05; = glucose infusion time. Nauck MA, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab. 1986;63: Copyright The Endocrine Society.
14 Insulin (mu/l) The Incretin Effect Is Reduced in Patients With Type 2 Diabetes Intravenous Glucose Oral Glucose 80 Control Subjects 80 Patients With Type 2 Diabetes * * * * * * * 20 * * * Time (min) Time (min) *P.05 compared with respective value after oral load. Nauck MA, et al. Diabetologia. 1986;29: Reprinted with permission from Springer-Verlag 1986.
15 Incretin hormones polypeptides secreted by cells in the small intestines in response to a meal major action is stimulation of insulin secretion in a glucose dependent manner also have negative influence on glucagon secretion and slow gastric emptying 2 principle hormones: GLP-1: Glucagon-like peptide- 1 GIP: Glucose insulinotropic polypeptide (gastric inhibitory peptide)
16 GLP-1 Effects in Humans: Understanding the Glucoregulatory Role of Incretins GLP-1 secreted upon the ingestion of food Promotes satiety and reduces appetite Alpha cells: Postprandial glucagon secretion Beta cells: Enhances glucosedependent insulin secretion Liver: Glucagon reduces hepatic glucose output Stomach: Helps regulate gastric emptying Adapted from Flint A, et al. J Clin Invest. 1998;101: ; Adapted from Larsson H, et al. Acta Physiol Scand. 1997;160: ; Adapted from Nauck MA, et al. Diabetologia. 1996;39: ; Adapted from Drucker DJ. Diabetes. 1998;47:
17 Multiple Actions of GLP-1 Act to Reduce Hyperglycaemia GLP-1 has multiple actions that reduce hyperglycaemia, including: Glucose-dependent stimulation of insulin secretion Glucose-dependent suppression of glucagon secretion Slowing of gastric emptying
18 GLP-1 is short-lived Rapid inactivation (DPP-IV), Short elimination half-life (~1-2 min) GLP-1 must be administered continuously (infusion) Need to extend action for therapeutic effect
19 Two pharmacological approaches 1. DPP-IV inhibitors extend action of native GLP-1 by inhibiting breakdown - oral agents but potential for off-target effects 2. DPP-IV resistant incretins extended action compared to native GLP-1 peptide therefore parenteral administration more predictable / specific action
20 The Therapeutic Potential of GLP-1 Is Limited by its Rapid Inactivation Rapid inactivation (DPP-IV), Short elimination half-life (~1-2 min) GLP-1 must be administered continuously (infusion) Inconvenient for treating a chronic disease like type 2 diabetes
21 Therapeutic approach to DPP-IV inhibition 1. Inhibit DPP-IV enhance the action of native GLP-1 Sitagliptin & Vildagliptin 2. Develop DPP-IV resistant GLP_1 analogues - exenatide: synthetic form of lizard exendin-4 - liraglutide analogue based on human GLP-1
22 DPP IV inhibitors -gliptins Five drugs now on UK market Effective - but modest improvements in A1c in clinical trials Weight neutral, but no associated weight loss in contrast to GLP-1 analogues Effective add-on to metformin - exact place in management not yet defined
23 GLP-1 Analogues Exenatide, Liraglutide, Lixisenatide There are now four licensed products in the UK Exenatide Liraglutide Lixisenatide Once weekly exenatide
24 Characteristics and function of GLP-1 analogues Action : Bind to human GLP-1 receptors to increase glucose- dependent insulin secretion Longer half life compared to native GLP-1 Resistant to DPP-IV degradation Slow gastric emptying Suppresses glucagon secretion Stimulate islet-cell neogenesis and proliferation Regulate food intake
25 Exenatide in UK practice Now widespread use Data colleceted in ABCD audit for over 5000 patients and initial presentations made based on 3913 patients Mean BMI 39 most on > 2 oral agents 999 patients on insulin 704 continued 861 total in audit used both exenatide and insulin
26 Mean HbA1c before, and last after, exenatide in 3054 patients p < HbA1c % % 8.65% 0.75% Before exenatide After exenatide
27 Mean weight before, and last after, exenatide in 2977 patients 120 p < Weight Kg kg kg 4.9 kg Before exenatide After exenatide
28 Number of patients Difference between last HbA1c after exenatide and HbA1c before exenatide >7% % 5% 4% 3% 2% 1% 0% -1% -2% -3% -4% -5% -6% -7% Change in HbA1c after exenatide
29 SGLT-2 inhibitors gliflozins A new class of drugs Dapagliflozin and Canagliflozin now in UK Work by inhibition of the glucose transport protein SGLT-2 in kidney The kidney filters and 200g glucose/day about 70g lost with SGLT-2 inhibition
30 Normal glucose homeostasis Net balance ~0 g/day Glucose input ~250 g/day: Glucose uptake ~250 g/day: Dietary intake ~180 g/day Glucose production ~70 g/day Gluconeogenesis Glycogenolysis Brain ~125 g/day Rest of the body ~125 g/day + The kidney filters circulating glucose The kidney reabsorbs and recirculates glucose Glucose filtered ~180 g/day Glucose reabsorbed ~180 g/day 1. Wright EM. Am J Physiol Renal Physiol 2001;280:F Gerich, JE. Diabetes Obes Metab 2000;2:
31 Normal renal glucose handling 1 3 Majority of glucose is reabsorbed by SGLT2 (90%) Proximal tubule SGLT2 Glucose Remaining glucose is reabsorbed by SGLT1 (10%) Minimal to no glucose excretion Glucose filtration SGLT, sodium-glucose co-transporter Wright EM. Am J Physiol Renal Physiol 2001;280:F10 18; 2. Lee YJ, et al. Kidney Int Suppl 2007;106:S27 35; 3. Hummel CS, et al. Am J Physiol Cell Physiol 2011;300:C14 21.
32 SGLT-2 inhibitors: A novel insulin-independent approach to remove excess glucose SGLT2 Dapagliflozin Proximal tubule InhibitorDapagliflozin SGLT2 Glucose Glucose filtration Increased urinary glucose excretion Dapagliflozin and Canagliflozin selectively inhibits SGLT2 in the renal proximal tubule FORXIGA Summary of Product Characteristics
33 HbA 1c change from baseline, % (mean adjusted for baseline values) Dapagliflozin addition to metformin: reductions in HbA 1c compared to placebo at 24 weeks Dapagliflozin 10 mg + metformin 0.84% ( 9 mmol/mol) (n=132) (95% Cl 0.98, 0.70%) Mean baseline HbA 1c 7.92% (63 mmol/mol) Placebo + metformin 0.30% ( 3 mmol/mol) (n=134) (95% Cl 0.44, 0.16%) 0.54% (6 mmol/mol) difference p< Mean baseline HbA 1c 8.11% (65 mmol/mol) HbA 1c change from baseline, mmol/mol (mean adjusted for baseline values) Adapted from Bailey CJ et al, Changes reported for Week 24 are adjusted for baseline values and are based on last observation carried forward (LOCF). CI, confidence interval. Bailey CJ et al. Lancet 2010; 375(9733):
34 HbA 1c (%) mean change from baseline Dapagliflozin addition to metformin: Reductions in HbA 1c were sustained over 102 weeks (n=133) (n=132) Primary endpoint Placebo + metformin (Mean baseline HbA 1c 8.11% [65 mmol/mol]) Dapagliflozin 10 mg + metformin (Mean baseline HbA 1c 7.92% [63 mmol/mol]) Study week +0.02% (0.2 mmol/mol) (95% Cl, 0.20 to 0.23%; n=28) 0.80% (8.8 mmol/mol) difference 0.78% ( 8.5 mmol/mol) (95% Cl, 0.97 to 0.60%; n=57) HbA 1c (mmol/mol) mean change from baseline 34 Adapted from Bailey CJ et al. Poster #988-P. Poster presented at 71 st Scientific Sessions of the American Diabetes Association, San Diego, California, June 24 28, 2011.
35 Adjusted mean change from baseline body weight (kg) Dapagliflozin: weight loss compared to placebo 24 weeks (LOCF analysis) 1 Dapagliflozin 10 mg + metformin 2.9 kg (n=133) 95% CI (-3.3 to -2.4) Placebo + metformin 0.9 kg (n=136) 95%CI -1.4 to kg difference p< weeks (repeated measures analysis) 2 Dapagliflozin 10 mg + metformin 1.70 kg (n=95) 95% Cl (-2.48 to -0.91) Placebo + metformin kg (n=73) 95% Cl (0.53 to 2.20) 3.1 kg difference p value not calculated Adapted from Bailey CJ, et al. (2010) & Bailey CJ, et al. (2011) 35
36 Metformin as first-line therapy First-line therapy in overweight and nonoverweight patients Some insulin sensitising properties Gastrointestinal side-effects occur 3 Contraindicated in renal or hepatic impairment
37 Next steps Sulphonylurea remains the appropriate second-line treatment for most patients DPP-IV and SGLT-2 are possible alternatives in specific cases Early escalation of treatment needed for many subjects failing oral treatment For many this will mean insulin but strong case for considering GLP-1 analogue treatment in the obese
Type 2 Diabetes. Aims and Objectives. What did you consider? Case Study One: Miss S. Which to choose?!?! Modes of Action
Aims and Objectives This session will outline the increasing complexities of diabetes care, and the factors that differentiate the combinations of therapy, allowing individualisation of diabetes treatment.
More informationNew and Future Treatments for Diabetes. Mary Charlton Specialty Doctor in Diabetes University Hospital Birmingham BARS Oct 2014
New and Future Treatments for Diabetes Mary Charlton Specialty Doctor in Diabetes University Hospital Birmingham BARS Oct 2014 Conflicts of interest Investigator Carmelina study of Linagliptin (Boehringer
More informationInsulin or GLP1 How to make this choice in Practice. Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust
Insulin or GLP1 How to make this choice in Practice Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust Workshop Over View Considerations/barriers to treatments in type 2
More informationlinagliptin, 5mg film-coated tablet (Trajenta ) SMC No. (746/11) Boehringer Ingelheim / Eli Lilly and Company Ltd
linagliptin, 5mg film-coated tablet (Trajenta ) SMC No. (746/11) Boehringer Ingelheim / Eli Lilly and Company Ltd 09 December 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of
More informationPharmaceutical Management of Diabetes Mellitus
1 Pharmaceutical Management of Diabetes Mellitus Diabetes Mellitus (cont d) Signs and symptoms 2 Elevated fasting blood glucose (higher than 126 mg/dl) or a hemoglobin A1C (A1C) level greater than or equal
More informationDIABETES MEDICATION-ORAL AGENTS AND OTHER HYPOGLYCEMIC AGENTS
Section Two DIABETES MEDICATION-ORAL AGENTS AND OTHER HYPOGLYCEMIC AGENTS This section will: Describe oral agents (pills) are specific for treating type 2 diabetes. Describe other hypoglycemic agents used
More information嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯
The Clinical Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Adults with Type 2 Diabetes Mellitus 嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯 Diabetes Mellitus : A group of diseases characterized
More informationtrends in the treatment of Diabetes type 2 - New classes of antidiabetic drugs. IAIM, 2015; 2(4): 223-
Review Article Pharmacological trends in the treatment of Diabetes type 2 - New classes of antidiabetic Silvia Mihailova 1*, Antoaneta Tsvetkova 1, Anna Todorova 2 1 Assistant Pharmacist, Education and
More informationType 2 Diabetes - Pros and Cons of Insulin Administration
Do we need alternative routes of insulin administration (inhaled insulin) in Type 2 diabetes? Cons: Suad Efendic Karolinska Institutet, Sweden The Diabetes Management Situation Today Diabetes is a growing
More informationINSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT?
INSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT? MARTHA M. BRINSKO, MSN, ANP-BC CHARLOTTE COMMUNITY HEALTH CLINIC CHARLOTTE, NC Diagnosed and undiagnosed diabetes in the United
More informationPharmacological Glycaemic Control in Type 2 Diabetes
Pharmacological Glycaemic Control in Type 2 Diabetes Aim(s) and Objective(s) This guideline aims to offer advice on the pharmacological management for those who require measures beyond diet and exercise
More informationUpdate on the management of Type 2 Diabetes
Update on the management of Type 2 Diabetes Mona Nasrallah M.D Assistant Professor, Endocrinology American University of Beirut 10 th Annual Family Medicine Conference October 14,2011 Global Prevalence
More information2011: New Drugs for Diabetes Treatment
Cardiology Update 2011 Davos, February 14, 2011 2011: New Drugs for Diabetes Treatment Roger Lehmann Department of Unresolved Problems in the Treatment of Type 2 Diabetes Diabetes Duration Consequences:
More informationDavid Shu, MD, FRCPC Endocrinology, Royal Columbian Hospital October 8 th, 2010
David Shu, MD, FRCPC Endocrinology, Royal Columbian Hospital October 8 th, 2010 Objectives At the end of the talk, the participants will be able to: 1. Identify the increasing prevalence of type 2 diabetes
More informationHarmony Clinical Trial Medical Media Factsheet
Overview Harmony is the global Phase III clinical trial program for Tanzeum (albiglutide), a product developed by GSK for the treatment of type 2 diabetes. The comprehensive program comprised eight individual
More informationSubcutaneous Infusion of GLP-1 for 7 Days Improves Glycemic Control Over a Broad Dose Range in Patients with Type 2 Diabetes
Subcutaneous Infusion of GLP-1 for 7 Days Improves Glycemic Control Over a Broad Dose Range in Patients with Type 2 Diabetes Mario R. Ehlers, 1,2 Roderick E. Harley, 1 Annette L. Mathisen, 1 Roberta Schneider,
More informationDipeptidyl Peptidase-IV Inhibitors: A New Drug in the Therapeutic Armamentarium for Treatment of Type 2 Diabetes Mellitus
REVIEW ARTICLE JIACM 2009; 10(3): 128-33 Dipeptidyl Peptidase-IV Inhibitors: A New Drug in the Therapeutic Armamentarium for Treatment of Type 2 Diabetes Mellitus Rajesh Rajput* Introduction The incidence
More informationType 2 Diabetes Medicines: What You Need to Know
Type 2 Diabetes Medicines: What You Need to Know Managing diabetes is complex because many hormones and body processes are at work controlling blood sugar (glucose). Medicines for diabetes include oral
More informationSecond- and Third-Line Approaches for Type 2 Diabetes Workgroup: Topic Brief
Second- and Third-Line Approaches for Type 2 Diabetes Workgroup: Topic Brief March 7, 2016 Session Objective: The objective of this workshop is to assess the value of undertaking comparative effectiveness
More informationSHORT CLINICAL GUIDELINE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SHORT CLINICAL GUIDELINE SCOPE 1 Guideline title Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes 1.1 Short title Type 2
More informationGliptins: a new class of oral hypoglycaemic agent. From the Department of Diabetes and Metabolism, The Royal London Hospital, London, UK
Q J Med 2007; 100:671 677 doi:10.1093/qjmed/hcm081 Review Gliptins: a new class of oral hypoglycaemic agent H. CHAHAL and T.A. CHOWDHURY From the Department of Diabetes and Metabolism, The Royal London
More informationDRUGS FOR GLUCOSE MANAGEMENT AND DIABETES
Page 1 DRUGS FOR GLUCOSE MANAGEMENT AND DIABETES Drugs to know are: Actrapid HM Humulin R, L, U Penmix SUNALI MEHTA The three principal hormones produced by the pancreas are: Insulin: nutrient metabolism:
More informationClinical Assistant Professor. Clinical Pharmacy Specialist Wesley Family Medicine Residency Program. Objectives
What s New in Diabetes Medications? Matthew Kostoff, PharmD, BCPS, BCACP Clinical Assistant Professor Clinical Pharmacy Specialist Wesley Family Medicine Residency Program Objectives Discuss new literature
More informationADJUNCTIVE THERAPIES FOR TYPE 1 DIABETES
ADJUNCTIVE THERAPIES FOR TYPE 1 DIABETES Dr. Mohammad Alhadj Ali, MD, PgDip, MSc, PhD (UK) with Prof. David Owens (UK) Outline Type 1 Diabetes Immunology of Type 1 Diabetes Treatment of Type 1 Diabetes
More informationmedications for type 2 diabetes
Talking diabetes No.25 Revised August 2010 medications for type 2 diabetes People with type 2 diabetes are often given medications including insulin to help control their blood glucose levels. Most of
More informationClinical Medicine: Therapeutics. Metformin: A Review of Its Use in the Treatment of Type 2 Diabetes. N. Papanas and E. Maltezos
Clinical Medicine: Therapeutics R e v i e w Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Metformin: A Review of Its Use in the Treatment of Type 2 Diabetes
More informationPrescribing for Diabetes. England 2005-06 to 2013-14
Prescribing for Diabetes England 2005-06 to 2013-14 Published 12 August 2014 We are the trusted national provider of high-quality information, data and IT systems for health and social care. www.hscic.gov.uk
More informationInitiate Atorvastatin 20mg daily
Type 2 Diabetes Patient Objectives Stopping Smoking BMI > 25 kg m² Control BP to
More informationCancer treatment and diabetes
Cancer treatment and diabetes Dr Daniel Morganstein Consultant Endocrinologist, 1 2 Diabetes and cancer Cancer and its treatment also poses challenges to managing diabetes Surgery Altered appetite Cachexia
More informationComparing Medications for Adults With Type 2 Diabetes Focus of Research for Clinicians
Clinician Research Summary Diabetes Type 2 Diabetes Comparing Medications for Adults With Type 2 Diabetes Focus of Research for Clinicians A systematic review of 166 clinical studies published between
More informationCASE A1 Hypoglycemia in an Elderly T2DM Patient with Heart Failure
Hypoglycemia in an Elderly T2DM Patient with Heart Failure 1 I would like to introduce you to Sophie, an elderly patient with long-standing type 2 diabetes, who has a history of heart failure, a common
More informationmedications for type 2 diabetes
Talking diabetes No.25 Revised 2012 medications for type 2 diabetes People with type 2 diabetes are often given medications including insulin to help manage their blood glucose levels. Most of these medications
More informationOverview of the Gliptin Class (Dipeptidyl Peptidase-4 Inhibitors) in Clinical Practice
clinical features Overview of the Gliptin Class (Dipeptidyl Peptidase-4 Inhibitors) in Clinical Practice Nancy Bohannon, MD 1 1 Monteagle Medical Center, San Francisco, CA Correspondence: Nancy Bohannon,
More informationA Guide to Monitoring Blood Glucose for Patients with diabetes in Care Homes
A Guide to Monitoring Blood Glucose for Patients with diabetes in Care Homes 1. Summary... 1 2. Background... 2 3. Purpose 2 4. Responsibilities. 2 5. Blood Glucose Monitoring. 2 6. Resident Groups that
More informationDistinguishing between Diabetes Mellitus Type 1 and Type 2, (with Overview of Treatment Strategies)
Distinguishing between Diabetes Mellitus Type 1 and Type 2, (with Overview of Treatment Strategies) Leann Olansky, MD, FACP, FACE Cleveland Clinic Endocrinology Glucose Tolerance Categories FPG Diabetes
More informationGlucose Tolerance Categories. Distinguishing between Diabetes Mellitus Type 1 and Type 2, (with Overview of Treatment Strategies)
Distinguishing between Diabetes Mellitus Type 1 and Type 2, (with Overview of Treatment Strategies) Leann Olansky, MD, FACP, FACE Cleveland Clinic Endocrinology Glucose Tolerance Categories FPG Diabetes
More informationHow To Treat Diabetes
Overview of Diabetes Medications Marie Frazzitta DNP, FNP c, CDE, MBA Senior Director of Disease Management North Shore LIJ Health Systems Normal Glucose Metabolism Insulin is produced by beta cells in
More informationTargeting the Kidney. Renal Glucose Transport 11/4/2015. Non insulin Agents Available IBITORS. Chao EC, et al. Nat Rev Drug Discovery. 2010;9:551 559.
SGLT-2i and DPP-IVi in the Management of Diabetes Mellitus Type 2 Abel Alfonso, D.O., F.A.C.E. Endocrinologist November 5, 2015 DIABETES: CURRENT RATES AND PROJECTIONS CDC Press Release 2010: 1 in 3 adults
More informationClinical Efficacy of Gliptins for Glycemic Control in Type 2 Diabeties Mellitus
World Applied Sciences Journal 7 (1): 01-06, 2009 ISSN 1818-4952 IDOSI Publications, 2009 REVIEW ARTICLE Clinical Efficacy of Gliptins for Glycemic Control in Type 2 Diabeties Mellitus 1 2 3 1 2 Atif Sitwat
More informationWhich drugs should be used to treat diabetes in cirrhotic patients?
Which drugs should be used to treat diabetes in cirrhotic patients? Frankfurt am Main 10-12 September 2015 Jörg Bojunga Medizinische Klinik I Johann Wolfgang Goethe-Universität Frankfurt am Main Significance
More informationSponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational.
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Investigational Study Number CLAF237A2386 Title A single-center,
More informationNew Non-Insulin Therapies for Type 2 Diabetes Mellitus
New Non-Insulin Therapies for Type 2 Diabetes Mellitus Ally P.H. Prebtani Associate Professor of Medicine Internal Medicine, Endocrinology & Metabolism McMaster University Canada Disclosure Relationships
More informationDiabetes in Primary Care course MCQ Answers 2016
Diabetes in Primary Care course MCQ Answers 2016 Diagnosis of Diabetes HbA1C should not be used as a diagnostic tool in the following situations: (answer each TRUE or FALSE) 1. Gestational Diabetes TRUE
More informationDiabetes Mellitus 1. Chapter 43. Diabetes Mellitus, Self-Assessment Questions
Diabetes Mellitus 1 Chapter 43. Diabetes Mellitus, Self-Assessment Questions 1. A 46-year-old man presents for his annual physical. He states that he has been going to the bathroom more frequently than
More informationTherapeutic Choices within Diabetes. Abeer Alsaweer, MBBS, CABFM*
Bahrain Medical Bulletin, Vol. 35, No. 2, June 2013 Education-Family Physician Corner Therapeutic Choices within Diabetes Abeer Alsaweer, MBBS, CABFM* The field of diabetes has experienced various evolutionary
More informationType 2 Diabetes and Prediabetes: A New Understanding of Cause and Treatment. Bruce Latham, M.D. Endocrine Specialists Greenville Health System
Type 2 Diabetes and Prediabetes: A New Understanding of Cause and Treatment Bruce Latham, M.D. Endocrine Specialists Greenville Health System Objectives for this presentation - Understand the thrifty genotype
More informationSweet-taste receptors, glucose absorption and insulin release: Are LCS nutritionally active?
Sweet-taste receptors, glucose absorption and insulin release: Are LCS nutritionally active? Samuel V. Molinary, Ph.D. Consultant, Scientific & Regulatory Affairs ILSI/NA April 6, 2011 Washington, DC Why
More informationof Treatment Options for Type 2 Diabetes Patients
Guidance Pack East Surrey CCG Guildford & Waverley CCG North West Surrey CCG Surrey Downs CCG Surrey Heath CCG North East Hampshire & Farnham CCG Crawley CCG Horsham & Mid-Sussex CCG of Treatment Options
More informationAvailable online through www.ijrap.net
Review Article Available online through www.ijrap.net GLUCAGON LIKE PEPTIDE 1: A NEW ERA IN TREATMENT OF TYPE- 2 DIABETES MELLITUS Singhal Manmohan* 1, Dave Rahul 1, Paul Arindam 2 * 1 School of Pharmaceutical
More informationDiabetes DIABETES MELLITUS. Types of Diabetes. Classification of Diabetes 6. 10. 2013. Prediabetes: IFG, IGT, Increased A1C
Diabetes Diabetes mellitus is a chronic disease characterized by high levels of blood glucose resulting from defects in insulin production, insulin action, or both. A state of raised blood glucose (hyperglycaemia)
More informationAntidiabetic Drugs. Mosby items and derived items 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc.
Antidiabetic Drugs Mosby items and derived items 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Diabetes Mellitus Two types Type 1 Type 2 Type 1 Diabetes Mellitus Lack of insulin production
More informationPrescribing for Diabetes, England 2005-06 to 2012-13
Prescribing for Diabetes, England 2005-06 to 2012-13 Published 13 August 2013 This product is relevant to members of the public and other stakeholders to support the understanding of primary care prescribing
More informationINSULIN INTENSIFICATION: Taking Care to the Next Level
INSULIN INTENSIFICATION: Taking Care to the Next Level By J. Robin Conway M.D., Diabetes Clinic, Smiths Falls, ON www.diabetesclinic.ca Type 2 Diabetes is an increasing problem in our society, due largely
More informationInsulin and Other Glucose-Lowering Drugs
Insulin and Other Glucose-Lowering Drugs I. OVERVIEW The pancreas is both an endocrine gland that produces the peptide hormones insulin, glucagon, and somatostatin and an exocrine gland that produces digestive
More informationTreatment Approaches to Diabetes
Treatment Approaches to Diabetes Dr. Sarah Swofford, MD, MSPH & Marilee Bomar, GCNS, CDE Quick Overview Lifestyle Oral meds Injectables not insulin Insulin Summary 1 Lifestyle & DM Getting to the point
More informationCASE B1. Newly Diagnosed T2DM in Patient with Prior MI
Newly Diagnosed T2DM in Patient with Prior MI 1 Our case involves a gentleman with acute myocardial infarction who is newly discovered to have type 2 diabetes. 2 One question is whether anti-hyperglycemic
More informationFrom history to reality: sodium glucose co-transporter 2 inhibitors a novel therapy for type 2 diabetes mellitus
Rev Goenka_Layout 1 04/08/2010 10:12 Page 1 From history to reality: sodium glucose co-transporter 2 inhibitors a novel therapy for type 2 diabetes mellitus S Nair, F Joseph, D Ewins, J Wilding, N Goenka*
More informationTHE PATHOPHYSIOLOGIC BASIS FOR DIABETES TREATMENT: EVALUATING THE EFFECT OF INCRETIN-BASED THERAPIES * Jack Leahy, MD
THE PATHOPHYSIOLOGIC BASIS FOR DIABETES TREATMENT: EVALUATING THE EFFECT OF INCRETIN-BASED THERAPIES * Jack Leahy, MD ABSTRACT Type 2 diabetes is a persistent public health challenge that requires innovative
More informationAntihyperglycemic Agents Comparison Chart
Parameter Metformin Sulfonylureas Meglitinides Glitazones (TZD s) Mechanism of Action Efficacy (A1c Reduction) Hepatic glucose output Peripheral glucose uptake by enhancing insulin action insulin secretion
More informationEffi cacy and Safety of Sitagliptin in the Treatment of Type 2 Diabetes
REVIEW Effi cacy and Safety of Sitagliptin in the Treatment of Type 2 Diabetes Roger Gadsby GP Nuneaton, Warwickshire U.K. and Associate Clinical Professor, Warwick Medical School, University of Warwick,
More informationNOUVELLLES THERAPIES EN DIABÈTE
1 NOUVELLLES THERAPIES EN DIABÈTE Rémi Rabasa-Lhoret M.D, Ph.D. Endocrinologie Chaire J-A De Sève Professeur agrégé, Département de nutrition, Université de Montréal Directeur Plateforme de Recherche en
More informationInsulin myths and facts
london medicines evaluation network Insulin myths and facts Statement 1 Insulin is the last resort for patients with Type 2 diabetes After initial metformin and sulfonylurea therapy, NICE and SIGN suggest
More informationCOMPASS Therapeutic Notes on the Newer Drugs used in the Management of Type 2 Diabetes Mellitus
COMPASS Therapeutic Notes on the Newer Drugs used in the Management of Type 2 Diabetes Mellitus In this issue Page Introduction and background 1 Thiazolidinediones 2 DPP-4 inhibitors (gliptins) 3 GLP-analogues
More informationDiabetes and stroke. What is diabetes? What are the symptoms of diabetes? Stroke Helpline: 0303 3033 100 Website: stroke.org.uk
Stroke Helpline: 0303 3033 100 Website: stroke.org.uk Diabetes and stroke Diabetes is a condition caused by too much sugar in your blood. There are over three million people in the UK who have diabetes.
More informationType 2 diabetes is a progressive. status
Type 2 diabetes is a progressive disease: its treatment the current status Associate Professor Jonathan Shaw Why is type 2 diabetes so hard to treat? How to choose the right glucose-lowering g drug? Page
More informationMary Bruskewitz APN, MS, RN, BC-ADM Clinical Nurse Specialist Diabetes
Mary Bruskewitz APN, MS, RN, BC-ADM Clinical Nurse Specialist Diabetes Objectives Pathophysiology of Diabetes Acute & Chronic Complications Managing acute emergencies Case examples 11/24/2014 UWHealth
More informationNoninsulin Diabetes Medications Summary Chart Medications marked with an asterisk (*) can cause hypoglycemia MED GROUP DESCRIPTOR
Noninsulin Diabetes Medications Summary Chart Medications marked with an asterisk (*) can cause MED GROUP DESCRIPTOR INSULIN SECRETAGOGUES Sulfonylureas* GLYBURIDE* (Diabeta) (Micronase) MICRONIZED GLYBURIDE*
More informationTrends in Prescribing of Drugs for Type 2 Diabetes in General Practice in England (Chart 1) Other intermediate and long-acting insulins
Type 2 Diabetes Type 2 diabetes is the most common form of diabetes, accounting for 90 95% of cases. 1 Charts 1 and 2 reflect the effect of increasing prevalence on prescribing and costs of products used
More informationInsulin use in Type 2 Diabetes. Dr Rick Cutfield. Why? When? How?
Insulin use in Type 2 Diabetes Dr Rick Cutfield Why? When? How? 1 Conflict of Interest I have been on advisory boards or had speaker fees from the following pharmaceutical companies: - Eli Lilly - Novo
More informationLiraglutide for the treatment of type 2 diabetes
DOI: 10.3310/hta15suppl1/09 Health Technology Assessment 2011; Vol. 15: Suppl. 1 77 Liraglutide for the treatment of type 2 diabetes D Shyangdan, 1 * E Cummins, 2 P Royle 1 and N Waugh 1 1 Department of
More informationManaging the risks of commencing insulin therapy for patients with type 2 diabetes
Managing the risks of commencing insulin therapy for patients with type 2 diabetes Laila King June 213 213 The Health Foundation Insulin is a remedy primarily for the wise, and not for the foolish, whether
More informationChallenges and Opportunities in the Treatment of Type 2 Diabetes. Nancy A. Thornberry
Challenges and Opportunities in the Treatment of Type 2 Diabetes Nancy A. Thornberry Relevant Disclosures Member of the Intarcia BOD Holds Merck stock Type 2 Diabetes: A Significant Unmet Medical Need
More informationManagement of Diabetes: A Primary Care Perspective. Presentation Outline
Management of Diabetes: A Primary Care Perspective Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Presentation Outline
More informationNew Developments of Anti-Diabetic Medications in 2013
UMDNJ New Developments of Anti-Diabetic Medications in 2013 Xiangbing Wang, MD., Ph.D. Division of Endocrinology & metabolism Robert Wood Johnson Medical School-UMDNJ (Rutgers), NJ, USA 1 Development and
More informationDIABETES EDUCATION. *Read package insert each time you refill your medications in case there is new information SULFONYLUREAS
DIABETES EDUCATION *Read package insert each time you refill your medications in case there is new information SULFONYLUREAS ACTION: Sulfonylureas stimulate the pancreas to make more insulin (pancreas
More informationAdd: 2 nd generation sulfonylurea or glinide or Add DPP-4 inhibitor Start or intensify insulin therapy if HbA1c goals not achieved with the above
Guidelines for Type Diabetes - Diagnosis Fasting Plasma Glucose (confirm results if borderline) HbAIC Normal FPG < 00 < 5.5 Impaired Fasting Glucose (IFG) 00 to < 5.7%-.5% Diabetes Mellitus (or random
More informationComparative Review of Oral Hypoglycemic Agents in Adults
SECTION 18.5 Comparative Review of Oral Hypoglycemic Agents in Adults Harinder Chahal For WHO Secretariat Table of Contents Acronyms:... 3 I. Background and Rationale for the review:... 4 II. Medications
More informationType II diabetes: How to use the new oral medications
Type II diabetes: How to use the new oral medications A TWO-PART INTERVIEW WITH NANCY J.V. BOHANNON, MD, BY DAVID B. JACK, MD Several new oral drugs have been approved for the management of type II diabetes.
More informationTake a moment Confer with your neighbour And try to solve the following word picture puzzle slides.
Take a moment Confer with your neighbour And try to solve the following word picture puzzle slides. Example: = Head Over Heels Take a moment Confer with your neighbour And try to solve the following word
More informationTreatment of Type 2 Diabetes: One Size Does Not Fit All
Treatment of Type 2 Diabetes: One Size Does Not Fit All Lisa Kroon, PharmD, CDE, FCSHP Professor and Chair, Clinical Pharmacy School of Pharmacy, University of California San Francisco Disclosure No conflict
More informationType 2 Diabetes - Referral Criteria to Specialist Services
Diabetes Pathway Contact Tel: 023 8028 6401 Fax: 023 8028 6407 Mon-Fri 9.00am-5.00pm Email: hp-tr.diabetes@nhs.net Consultants email: kate.fayers@southernhealth.nhs.uk hermione.price@southernhealth.nhs.uk
More informationTreatment of Type 2 Diabetes
Improving Patient Care through Evidence Treatment of Type 2 Diabetes This information is based on a comprehensive review of the evidence for best practices in the treatment of type 2 diabetes and is sponsored
More informationVolume 01, No. 08 November 2013
State of New Jersey Department of Human Services Division of Medical Assistance & Health Services New Jersey Drug Utilization Review Board Volume 01, No. 08 November 2013 TO: SUBJECT: PURPOSE: Physicians,
More informationMedicines for Type 2 Diabetes A Review of the Research for Adults
Medicines for Type 2 Diabetes A Review of the Research for Adults Is This Information Right for Me? Yes, if: Your doctor or health care provider has told you that you have type 2 diabetes and have high
More informationGLP-1 based therapies: differential effects on fasting and postprandial glucose
Diabetes, Obesity and Metabolism 14: 675 688, 2012. 2012 Blackwell Publishing Ltd GLP-1 based therapies: differential effects on fasting and postprandial glucose review article M. S. Fineman 1,B.B.Cirincione
More informationCase study: Adult who is newly diagnosed with type 2 diabetes and at risk of hypoglycaemia
Case study: Adult who is newly diagnosed with type 2 diabetes and at risk of hypoglycaemia Authored by Lawrence Leiter and Edward Horton on behalf of the Global Partnership for Effective Diabetes Management.
More informationType 2 Diabetes - Pramlintide and Exenatide
Therapies for Diabetes: Pramlintide and Exenatide MELISSA C. JONES, PharmD, BCPS, South University School of Pharmacy, Savannah, Georgia The American Diabetes Association currently recommends an A1C goal
More informationSubmitted to Expert Opinion on Drug Metabolism & Toxicology
Submitted to Expert Opinion on Drug Metabolism & Toxicology Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease André J. Scheen University of Liège,
More informationEnd of Life Diabetes Care
End of Life Diabetes Care Commissioned by Diabetes UK Supplementary Documents and Flowcharts Endorsed By: Diabetes Phases of End of Life and Medications A - Blue: All From Diagnosis Stable With Year Plus
More informationDiet and Medication Therapy in the Treatment of Type 2 Diabetes
Basiratu Ibrahim & Folake Mashopa Diet and Medication Therapy in the Treatment of Type 2 Diabetes Comparison between Finland and the United States of America (USA) Thesis Spring 2015 Seinäjoki University
More informationThe Treatment of Type 2 Diabetes Andreas F. H. Pfeiffer, Harald H. Klein
CONTINUING MEDICAL EDUCATION The Treatment of Type 2 Diabetes Andreas F. H. Pfeiffer, Harald H. Klein SUMMARY Background: 5% to 8% of adults have type 2 diabetes, a disease that is usually asymptomatic
More informationPANCREATIC HORMONES. Mr. D.Raju, M.pharm, Lecturer
PANCREATIC HORMONES Mr. D.Raju, M.pharm, Lecturer Insulin; Glucagon Diabetes Mellitus 2 types: - Type I; juvenile onset; IDDM - Type II; maturity onset; IIDM Symptomatology: -Early -Late Early manifestations:
More informationConsensus Statement for the Management of Type 2 Diabetes
William T. Cefalu, M.D. Profess of Diabetes Associate Executive Direct of Scientific Affairs Chief Scientific Officer Pennington Biomedical Research Center Consensus Statement f the Management of Type
More informationDr. Robyn Houlden Professor, Division of Endocrinology Queen s University
Diabetes in the elderly Dr. Robyn Houlden Professor, Division of Endocrinology Queen s University Disclosures Grants/research support: AstraZeneca, Eli Lilly, Pfizer Speakers bureau/honoraria: NovoNordisk,
More informationLiraglutide: First Once-daily human GLP-1 analogue
Liraglutide: First Once-daily human GLP-1 analogue * Dr. Sreejith N Kumar Current status of type 2 diabetes in India and unmet needs As per the latest International Diabetes Federation (IDF) released in
More informationCME Test for AMDA Clinical Practice Guideline. Diabetes Mellitus
CME Test for AMDA Clinical Practice Guideline Diabetes Mellitus Part I: 1. Which one of the following statements about type 2 diabetes is not accurate? a. Diabetics are at increased risk of experiencing
More informationCara Liday, PharmD, CDE Associate Professor, Idaho State University Clinical Pharmacist and CDE, InterMountain Medical Center Pocatello, ID The planners and presenter have disclosed no conflict of interest,
More informationInternational Journal of Pharmacy and Pharmaceutical Sciences
International Journal of Pharmacy and Pharmaceutical Sciences Vol 2, Suppl 1, 2010 DIABETES MELLITUS TYPE II: REVIEW OF ORAL TREATMENT OPTIONS Review Article Rana Ibrahim Lecturer in Pharmacy Practice/
More informationEFFIMET 1000 XR Metformin Hydrochloride extended release tablet
BRAND NAME: Effimet XR. THERAPEUTIC CATEGORY: Anti-Diabetic PHARMACOLOGIC CLASS: Biguanides EFFIMET 1000 XR Metformin Hydrochloride extended release tablet COMPOSITION AND PRESENTATION Composition Each
More information